09 Mar 2023 - Sequoia Financial Group Limited (ASX:SEQ) CEO and Managing Director Garry Crole discusses the 80 per cent sale of Morrison Securities to New Quantum.
07 Mar 2023 - Eureka Group Holdings Limited (ASX:EGH) CEO Cameron Taylor provides an overview of the company, discussing positioning in the industry, strategy, the new development in Brassall, Queensland, government assistance and growth opportunities.
06 Mar 2023 - Keith Cullen, Founder and Managing Director of WT Financial Group Limited (ASX:WTL) discusses the company's half-year results, why the rising cost of financial advice is good for the profession, the company's direct-to-consumer channel, the Quality of Advice Review, the prospects for further acquisitions, and dividends.
03 Mar 2023 - IVE Group Limited (ASX:IGL) Executive Chairman Geoff Selig discusses the company's half-year financial results, commenting on key drivers, the Lasoo platform launch, the Ovato acquisition and the company's partnership with Iberdrola.
02 Mar 2023 - Scott Kelly, RAM CEO Australia, provides an introduction to the RAM Essential Services Property Fund (ASX:REP), discussing geographical spread, yield, investment strategy, financials and inflation.
01 Mar 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.
21 Feb 2023 - BluGlass Limited (ASX:BLG) President Jim Haden provides an update on the company, discussing the launch of the company's first suite of laser products, integration of the recently acquired fab facility and outlook for 2023.
20 Feb 2023 - Etherstack Limited (ASX:ESK) CEO and Executive Director David Deacon discusses the company's 2022 financial highlights and outlook for 2023.
17 Feb 2023 - Shaw and Partners Chief Investment Officer Martin Crabb discusses financial conditions, the outlook for growth, central bank monetary policy, and what this means for portfolio construction.
17 Feb 2023 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the company's upcoming plans to list on the NASDAQ and provides an update on the its clinical trials.
